ClinicalTrials.Veeva

Menu

Probiotics Strains for Infant Colic

U

Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude

Status and phase

Enrolling
Phase 2

Conditions

Colic

Treatments

Dietary Supplement: Placebo
Dietary Supplement: Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863
Dietary Supplement: Limosilactobacillus reuteri CCT 7862

Study type

Interventional

Funder types

Other

Identifiers

NCT05685030
63543922.2.0000.0119

Details and patient eligibility

About

Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies.

Therefore, based on data in the literature, it is understood that there is evidence of the effectiveness of using probiotics, either alone or in the form of a blend, to alleviate the symptoms of infantile colic.

Full description

Infantile colic represents a self-limiting temporary condition, which occurs in about one in five babies in the first few months of life, and is characterized by inconsolable crying and fussiness of unknown cause. Despite its benign nature, infantile colic serves as a significant source of maternal anxiety and depression, impaired family functioning, and the most common reason for seeking medical advice in this age group. Infant colic is also associated with sleep problems in babies.

Parents and caregivers often seek medical attention for colic, including the use of medication, plant fiber, lactase, sucrose solution, hypoallergenic diet, and herbal tea. However, there is no single effective and safe intervention for infantile colic.

Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies. Thus, several researchers have suggested that probiotics may be useful in treating breastfed babies with colic and reducing crying time.

One study showed that administration of Lactobacillus reuteri DSM 17938 improved colic symptoms, although the effectiveness was only seen in breastfed and not formula fed infants. Another study showed that treatment with a combination of L. casei, L. rhamnosus, Streptococcus thermophilus, B. breve, L. acidophilus, B. infantiles, L. bulgaricus and fructooligosaccharides (FOS) reduced the duration of crying by almost 35 min compared to placebo. Furthermore, other authors has reported a reduced incidence of caregiver-reported colic when infants were supplemented with a combination of B. animalis subsp. lactis BB-12 and an unidentified strain of S. thermophilus, although colic was not formally diagnosed by a physician, which reduced the strength of the studies. A recent study on the same BB-12 strain overcame this deficiency by formally diagnosing colic using Rome-III criteria. However, this study showed that the response rate did not significantly improve over placebo until day 21. On the other hand, one study reported that the use of L. rhamnosus GG (ATCC53103) had no significant effect on crying in babies with colic. In another study, no significant differences were found in crying and irritability between the probiotic and placebo groups when supplemented with L. reuteri ATCC55730 or B. lactis BB-12.

Enrollment

180 estimated patients

Sex

All

Ages

17 to 23 days old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 20 days ± 3 days.
  • Informed consent form signed by parents
  • Both gender
  • Availability to complete scales daily and answer phone calls and/or text messages.

Exclusion criteria

  • Birth weight <2500 g;
  • current intake of antibiotics, prebiotics, or probiotics by the baby or mother;
  • Children with known moderate or severe disease of any system (neural, skeletal, muscular, cutaneous, gastrointestinal, respiratory, genital, urinary, immune),
  • parental difficulty in understanding study requirements as judged by physician.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

180 participants in 3 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
product vehicle (sunflower oil)
Treatment:
Dietary Supplement: Placebo
Limosilactobacillus reuteri CCT 7862
Experimental group
Description:
Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ daY.
Treatment:
Dietary Supplement: Limosilactobacillus reuteri CCT 7862
Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863
Experimental group
Description:
Blend: Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day.
Treatment:
Dietary Supplement: Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems